Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
OwnerAlan Leffinventor
Life of this patent
Estimating the term…
Abstract
Methods for treating or modulating inflammatory processes or chronic inflammatory conditions dependent upon cellular inflammation, such as asthma and rheumatoid arthritis are provided, as well as methods for inhibiting or blocking eosinophil migration and airway hyperresponsiveness. Also described is a method for treating or preventing the adhesion of granulocytes and other inflammatory cells into the tissue that is the site of the inflammation. In particular, the methods relate to the therapeutic or prophylactic use of compounds and compositions that inhibit cytosolic phospholipase A2.
Claims9
A method for reducing inflammation in a patient, comprising:
- administering a compound that reduces an activity of cytosolic phospholipase A2 (cPLA2) in combination with a pharmaceutically acceptable carrier.
A method for reducing migration of white blood cells into tissues, comprising:
- reducing adhesion of the white blood cells and diapedesis into tissues by administering a compound that reduces an activity of cytosolic phospholipase A2 (cPLA2) in combination with a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a compound that inhibits the serine-228 residue of cPLA2.
Dependencies are inferred from the claim text.